Benjamin Haaland
Molecular Biology · 2014–2017
A researcher in the Science corpus: 2 papers; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 21 citations into it
- Artificial Intelligence — 7 citations into it
Whom Benjamin Haaland trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- Tom Fawcett (in Artificial Intelligence)
- Max Kuhn (in Molecular Biology)
- C. Burges (in Statistical Learning Theory)
Papers from Benjamin Haaland's perspective
Ordered by how strongly the researchers Benjamin Haaland trusts endorse each paper. Same corpus, a different order for every researcher.
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (New England Journal of Medicine)
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (New England Journal of Medicine)
- An introduction to ROC analysis
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (Clinical Cancer Research)
- Building Predictive Models in R Using the caret Package
- A Tutorial on Support Vector Machines for Pattern Recognition
- Data Mining - Concepts and Techniques (Künstliche Intell.)
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. (Journal of Clinical Oncology)
- Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. (New England Journal of Medicine)
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. (The Lancet Oncology)